- ISIN
- US6033801068
- CUSIP
- 603380106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 1, 2014
Highlights
- Market Cap
- $190.96M
- Enterprise Value
- -$32.47B
- EPS (TTM)
- -$7.17K
- Gross Profit (TTM)
- -$2.72K
- EBITDA (TTM)
- -$16.68B
- Year Range
- $1.57 - $12.46
- Target Price
- $5.00
- ROA (TTM)
- -133.68%
- ROE (TTM)
- 50.47%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NERV Performance Chart
Minerva Neurosciences, Inc. (NERV) is up 8.2% since the beginning of the year. At $4 per share, NERV is trading 65.1% below its 52-week high of $12. Investors who bought $1,000 worth of NERV shares 5 years ago would now be looking at an investment worth $219.
Loading charts...
Returns By Period
Minerva Neurosciences, Inc. (NERV) has returned 8.21% so far this year and 145.76% over the past 12 months. Over the last ten years, NERV has returned -25.43% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.
Minerva Neurosciences, Inc.
- 1D
- -6.65%
- 1M
- -17.30%
- YTD
- 8.21%
- 6M
- 7.14%
- 1Y
- 145.76%
- 3Y*
- -10.71%
- 5Y*
- -26.18%
- 10Y*
- -25.43%
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
NERV Monthly Returns History
Based on dividend-adjusted daily data since Jul 1, 2014, NERV's average daily return is +0.17%, while the average monthly return is +3.19%. At this rate, an investment would double in approximately 1.8 years.
Historically, 43% of months were positive and 57% were negative. The best month was Aug 2022 with a return of +320.9%, while the worst month was Oct 2022 at -71.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, NERV closed higher 45% of trading days. The best single day was May 26, 2016 with a return of +233.3%, while the worst single day was May 29, 2020 at -72.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.00% | 62.56% | -8.71% | 7.39% | -24.11% | -11.41% | 8.21% | ||||||
| 2025 | 3.98% | -27.71% | 1.80% | -1.76% | -7.78% | 11.69% | 8.72% | 26.20% | -10.81% | 99.52% | -0.48% | -3.83% | 80.95% |
| 2024 | 37.40% | -68.40% | -3.37% | -8.53% | 8.06% | 25.10% | -6.90% | -7.74% | -2.55% | -10.30% | -5.85% | -1.48% | -63.88% |
| 2023 | 50.31% | -9.62% | -25.93% | 75.00% | 113.21% | 53.10% | 4.05% | -11.99% | -17.56% | -30.14% | 62.86% | -21.66% | 286.79% |
| 2022 | 3.05% | -14.44% | 17.56% | -38.61% | -21.52% | 3.44% | -19.03% | 320.90% | -18.17% | -71.29% | 33.58% | -55.08% | -75.19% |
| 2021 | 36.32% | -2.82% | -5.81% | -18.49% | 23.95% | -21.36% | -20.69% | -0.00% | -5.43% | -19.54% | -30.64% | -17.51% | -65.77% |
Benchmark Metrics
Minerva Neurosciences, Inc. has an annualized alpha of 36.45%, beta of 0.86, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 01, 2014.
- This stock participated in 122.19% of S&P 500 Index downside but only -1.50% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 36.45%
- Beta
- 0.86
- R²
- 0.01
- Upside Capture
- -1.50%
- Downside Capture
- 122.19%
Return for Risk
Risk / Return Rank
NERV ranks 83 for risk / return — in the top 83% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Minerva Neurosciences, Inc. (NERV) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NERV | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.92 | ||
| Sortino ratioReturn per unit of downside risk | +0.92 | ||
| Omega ratioGain probability vs. loss probability | 1.40 | 1.32 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | 2.97 | 2.46 | +0.52 |
| Martin ratioReturn relative to average drawdown | 5.58 | 10.92 | -5.34 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Minerva Neurosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Minerva Neurosciences, Inc. was 98.86%, occurring on Apr 9, 2025. The portfolio has not yet recovered.
The current Minerva Neurosciences, Inc. drawdown is 96.30%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -98.86%Apr 2025 | 4y 10mo | — | 6y 29dMay 2020 - now |
2019 bear market2019 | -71.63%Oct 2019 | 3y 1mo | 7mo 2d | 3y 8moSep 2016 - May 2020 |
2016 bear market2016 | -53.73%May 2016 | 1y 8mo | 1d | 1y 8moSep 2014 - May 2016 |
2016 bear market2016 | -33.29%Jun 2016 | 24d | 2mo 25d | 3mo 19dJun 2016 - Sep 2016 |
2014 correction2014 | -17.13%Aug 2014 | 7d | 1mo 5d | 1mo 12dJul 2014 - Sep 2014 |
Drawdown Indicators
| NERV | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.86% | -56.78% | -42.08% |
Max Drawdown (1Y)Largest decline over 1 year | -49.30% | -9.10% | -40.20% |
Max Drawdown (3Y)Largest decline over 3 years | -89.73% | -18.90% | -70.83% |
Max Drawdown (5Y)Largest decline over 5 years | -93.22% | -25.43% | -67.79% |
Max Drawdown (10Y)Largest decline over 10 years | -98.86% | -33.92% | -64.94% |
Current DrawdownCurrent decline from peak | -96.30% | -3.21% | -93.09% |
Average DrawdownAverage peak-to-trough decline | -65.43% | -10.71% | -54.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.22% | 2.04% | +24.18% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Minerva Neurosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Minerva Neurosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NERV
Add Minerva Neurosciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NERV